Nykredit A S Makes New Investment in Insulet Corporation $PODD

Key Points

• Nykredit A/S acquired 31,942 Insulet shares during the second quarter, valued at approximately $4.86 million.
• Analyst sentiment is mixed: Insulet has a consensus “Hold” rating and an average price target of $195.40, while several firms recently lowered targets or ratings.
• Insulet reported quarterly earnings of $1.66 per share, surpassing estimates, while revenue rose 23.5% year over year to $801.7 million. Shares opened at $140.53, near the lower end of their 52-week range.

Nykredit A S acquired a new position in Insulet Corporation (NASDAQ:PODD - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 31,942 shares of the medical instruments supplier's stock, valued at approximately $4,863,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Larson Financial Group LLC grew its stake in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after acquiring an additional 47 shares during the period. MV Capital Management Inc. purchased a new stake in shares of Insulet in the 4th quarter valued at about $29,000. Fideuram Asset Management Ireland dac purchased a new stake in Insulet in the fourth quarter valued at approximately $41,000. Continuum Advisory LLC bought a new position in Insulet in the second quarter valued at $46,000. Finally, Sound Income Strategies LLC raised its position in Insulet by 4,620.0% during the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 231 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PODD. Oppenheimer lowered Insulet from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. TD Cowen dropped their target price on Insulet from $294.00 to $144.00 and set a "hold" rating for the company in a research report on Thursday, August 6th. Citigroup upped their target price on Insulet from $165.00 to $172.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 8th. Sanford C. Bernstein reduced their price target on shares of Insulet from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Finally, Stifel Nicolaus lowered their price objective on shares of Insulet from $225.00 to $180.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $195.40.

Insulet Price Performance

Shares of NASDAQ PODD opened at $140.53 on Tuesday. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The stock has a market capitalization of $9.75 billion, a P/E ratio of 26.27, a P/E/G ratio of 1.11 and a beta of 1.08. The company's 50-day moving average is $149.96 and its 200 day moving average is $168.89. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period in the previous year, the company posted $1.17 earnings per share. The firm's revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts expect that Insulet Corporation will post 6.51 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.